

INTRODUCTION

This document includes your personal details and your declaration of interests to be made public in line with the provisions of the ENCePP Code of Conduct. All parts must be duly completed. You are responsible for the accuracy and completeness of the submitted information.

The form is designed to be filled in electronically; a copy of the form should be uploaded to the $\underline{\text{EU PAS}}$ Register.

For ENCePP Seal studies only: the completed form is to be transmitted to the ENCePP Secretariat by email.

SECTION 1: PERSONAL DETAILS

First Name:	Henrik
Last Name:	Svanström
Organisation / Research Centre :	IQVIA
Country:	Denmark
Contact e-mail Address:	henrik.svanstroem@iqvia.com
	A non-interventional register-based comparative effectiveness study of rhFSH-alfa reference product vs. highly purified human menopausal gonadotropin or rhFSH-alfa biosimilar products for ovarian stimulation in in vitro fertilization or intracytoplasmic sperm injection treatment in Denmark and Sweden – The Nordic Follitropin Alfa Comparative Effectiveness (NORD-FACE) Study
Study Reference Number: I	EUPAS 4 1 1 7 5
Are you the (Primary) Lead	Investigator of the above study? No \square Yes \checkmark
Are you an investigator/res	earcher contributing to the above study No 📝 Yes 🗍

SECTION 2: DECLARATION OF INTERESTS RELATED TO PHARMACEUTICAL INDUSTRY In this section you must declare any interests in the pharmaceutical industry that you currently have or had within the past 3 years. If you have interests to declare please tick 'Yes' to the relevant questions. All questions in this part must be answered. 2.1 Employment No (7) Yes (Employment in a pharmaceutical company during past 3 years of study application? Pharmaceutical company includes supply or service companies which contribute to research, development, production and maintenance of a medicinal product. Employment relates to salaries currently being directly paid to you by a pharmaceutical company. No (Yes (2.2 Financial Interest Financial interests in the capital of a pharmaceutical company? Financial interests relate to current holding of shares of a pharmaceutical company with the exclusion of independently managed investment funds/pensions schemes that are not exclusively based on the pharmaceutical sector. 2.3 Patent No 🕢 Yes () Patent for a medicinal product? Relates to a patent for a medicinal product currently owned by either you as individual or your organisation/ research centre, and you as individual are the beneficiary. 2.4 Consultancy No () Yes 🕢 Consultancy for a pharmaceutical company during the past 3 years of study application? Consultancy refers to provision of advice or services to a pharmaceutical company excluding the concerned study and including but not limited to reviewing activities, data monitoring, statistical analysis, end point committees, regardless of contractual arrangements or any form of remuneration such as consulting fees or honoraria. Note that conference/seminar attendance is not considered a consultancy but should be indicated if subject to fee or honorarium. Please specify the pharmaceutical company, types of consultancy and dates when fees/honoraria paid: Period: Current Past 06 From Year: 2018 From Month: To Month: 12 To Year: 2018 Name of Pharmaceutical Company: Celgene Epidemiological and statistical analyses. Fees from Celgene Type of consultancy: were received on February 8, 2019, March 8, 2019 and April 23, 2019. Please specify the pharmaceutical company, types of consultancy and dates when fees/honoraria paid: Period: Current Past 12 From Month: From Year: 2018 Name of Pharmaceutical Company: Multiple IOVIA is a contract research organization that performs Type of consultancy: commissioned pharmacoepidemiological studies and thus its employees have been and currently are working in collaboration with several pharmaceutical companies. 2.5 Strategic Advisory Role No 🕢 Yes ()

Strategic Advisory role on activities of a pharmaceutical company during the past 3 years of study application?

Participation with the right to vote on/influence the output in a (scientific) advisory board/steering committee with the role of providing advice/expressing opinions on the future strategy, direction or development activities of a pharmaceutical company either in terms of general or product-related strategy, regardless of contractual arrangements or any form of remuneration.

Refers to a grant or funding from a pharmaceutical company which is currently being received by your research group, irrespective of whether you are employed or a volunteer, and you receive no personal gain.
SECTION 3: ANY OTHER INTERESTS No Yes
In this section you should declare any other interests of commercial, financial, institutional or personal nature to be made known to the public.*
Any other relationships/conditions/circumstances that present a potential conflict of interest, including matters relating to members of your family? (*see definition in Annex 1 of ENCePP Code of Conduct)
Further to the interests declared above, I do hereby declare on my honour that I do not have any further interests or facts that should be made public in relation to the conduct of the study.
Should there be any change of the above due to the fact that I acquire additional interests, I shall promptly complete and upload a new Declaration of Interests detailing the changes.
\checkmark I confirm the information declared on this form is accurate to the best of my knowledge and I consent to my information being stored electronically and published on the <u>EU PAS Register</u> .
FULL NAME: Henrik Svanström Date: 14/06/2021
Submit Form by Email

Grant/funding from a pharmaceutical company other than funds contemplated in the concerned

No 🕢 Yes 🔘

2.6 Grant / Funding

study contract?



INTRODUCTION

This document includes your personal details and your declaration of interests to be made public in line with the provisions of the ENCePP Code of Conduct. All parts must be duly completed. You are responsible for the accuracy and completeness of the submitted information.

The form is designed to be filled in electronically; a copy of the form should be uploaded to the $\underline{\text{EU PAS}}$ Register.

For ENCePP Seal studies only: the completed form is to be transmitted to the ENCePP Secretariat by email.

SECTION 1: PERSONAL DETAILS

First Name:	Anna
Last Name:	Westerlund
Organisation / Research Centre :	IQVIA
Country:	Sweden
Contact e-mail Address:	anna.westerlund@iqvia.com
	A non-interventional register-based comparative effectiveness study of rhFSH-alfa reference product vs. highly purified human menopausal gonadotropin or rhFSH-alfa biosimilar products for ovarian stimulation in in vitro fertilization or intracytoplasmic sperm injection treatment in Denmark and Sweden – The Nordic Follitropin Alfa Comparative Effectiveness (NORD-FACE) Study
Study Reference Number: I	EUPAS 4 1 1 7 5
Are you the (Primary) Lead	Investigator of the above study? No \checkmark Yes
Are you an investigator/res	earcher contributing to the above study No Yes

SECTION 2: DECLARATION	OF INTERESTS REI	LATED T	О РНА	RMACEUTICAL	INDUSTRY
In this section you must declare any i past 3 years. If you have interests to be answered.					
2.1 Employment		No 🕢	Yes 🔘		
Employment in a pharmaceutic Pharmaceutical company includes sup and maintenance of a medicinal produpharmaceutical company.	ply or service companies	s which co	ntribute t	to research, develop	ment, production
2.2 Financial Interest		No 🕢	Yes 🔘		
Financial interests in the capit Financial interests relate to current he managed investment funds/pensions	olding of shares of a pha	rmaceutica	al compar		
2.3 Patent		No 🕢	Yes 🔘		
Patent for a medicinal product Relates to a patent for a medicinal procentre, and you as individual are the	oduct currently owned by	y either yo	u as indi	vidual or your organ	isation/ research
2.4 Consultancy		No 🔘	Yes 🕢		
Consultancy for a pharmaceutic Consultancy refers to provision of advincluding but not limited to reviewing of contractual arrangements or any for Note that conference/seminar attendation to the conference of t	vice or services to a phar activities, data monitorion from of remuneration sucl	maceutical ng, statisti n as consu	l compan cal analy Iting fees	ny excluding the condrsis, end point comm s or honoraria.	cerned study and ittees, regardless
Please specify the pharmaceutical compan	y, types of consultancy and	dates wher	n fees/hon	noraria paid:	
Period:	Past				
From Month: 07 From Year: 20	017				
Name of Pharmaceutical Company:	Multiple				
Type of consultancy:	IQVIA is a contract rese commissioned pharmacc employees have been a collaboration with sever	pepidemiol nd currentl	logical stu ly are wo	udies and thus its orking in	
2.5 Strategic Advisory Role		No 🕢	Yes 🔘		
Strategic Advisory role on activities of a pharmaceutical company during the past 3 years of study application? Participation with the right to vote on/influence the output in a (scientific) advisory board/steering committee with the role of providing advice/expressing opinions on the future strategy, direction or development activities of a pharmaceutical company either in terms of general or product-related strategy, regardless of contractual arrangements					

or any form of remuneration.

Grant/funding from a pharmaceutical company other than funds contemplated in the concerned study contract?

Refers to a grant or funding from a pharmaceutical company which is currently being received by your research group, irrespective of whether you are employed or a volunteer, and you receive no personal gain.

SECTION 3: ANY OTHER INTERESTS	No 🕢	Yes 🔘	
In this section you should declare any other	interest	s of commercial, financial,	

institutional or personal nature to be made known to the public.*

Any other relationships/conditions/circumstances that present a potential conflict of interest, including matters relating to members of your family? (*see definition in Annex 1 of ENCePP Code of Conduct)

Further to the interests declared above, I do hereby declare on my honour that I do not have any further interests or facts that should be made public in relation to the conduct of the study.

Should there be any change of the above due to the fact that I acquire additional interests, I shall promptly complete and upload a new Declaration of Interests detailing the changes.

✓ I confirm the information declared on this form is accurate to the best of my knowledge and I consent to my information being stored electronically and published on the <u>EU PAS Register</u>.

FULL NAME: Anna Westerlund Date: 15/06/2021

Submit Form by Email



INTRODUCTION

This document includes your personal details and your declaration of interests to be made public in line with the provisions of the ENCePP Code of Conduct. All parts must be duly completed. You are responsible for the accuracy and completeness of the submitted information.

The form is designed to be filled in electronically; a copy of the form should be uploaded to the $\underline{\text{EU PAS}}$ Register.

For ENCePP Seal studies only: the completed form is to be transmitted to the ENCePP Secretariat by email.

SECTION 1: PERSONAL DETAILS

First Name:	Julia
Last Name:	Pietilä
Organisation / Research Centre :	IQVIA
Country:	Finland
Contact e-mail Address:	julia.pietila@iqvia.com
	A non-interventional register-based comparative effectiveness study of rhFSH-alfa reference product vs. highly purified human menopausal gonadotropin or rhFSH-alfa biosimilar products for ovarian stimulation in in vitro fertilization or intracytoplasmic sperm injection treatment in Denmark and Sweden – The Nordic Follitropin Alfa Comparative Effectiveness (NORD-FACE) Study
Study Reference Number:	EUPAS 4 1 1 7 5
Are you the (Primary) Lead	Investigator of the above study? No 🗸 Yes
Are you an investigator/res	searcher contributing to the above study No 🗍 Yes 📝

SECTION 2: DECLARATION OF INTERESTS RELATED TO PHARMACEUTICAL INDUSTRY In this section you must declare any interests in the pharmaceutical industry that you currently have or had within the past 3 years. If you have interests to declare please tick 'Yes' to the relevant questions. All questions in this part must be answered. No V Yes 2.1 Employment Employment in a pharmaceutical company during past 3 years of study application? Pharmaceutical company includes supply or service companies which contribute to research, development, production and maintenance of a medicinal product. Employment relates to salaries currently being directly paid to you by a pharmaceutical company. 2.2 Financial Interest No (7) Yes (Financial interests in the capital of a pharmaceutical company? Financial interests relate to current holding of shares of a pharmaceutical company with the exclusion of independently managed investment funds/pensions schemes that are not exclusively based on the pharmaceutical sector. 2.3 Patent No (V) Yes (Patent for a medicinal product? Relates to a patent for a medicinal product currently owned by either you as individual or your organisation/ research centre, and you as individual are the beneficiary. 2.4 Consultancy No () Yes () Consultancy for a pharmaceutical company during the past 3 years of study application? Consultancy refers to provision of advice or services to a pharmaceutical company excluding the concerned study and including but not limited to reviewing activities, data monitoring, statistical analysis, end point committees, regardless of contractual arrangements or any form of remuneration such as consulting fees or honoraria. Note that conference/seminar attendance is not considered a consultancy but should be indicated if subject to fee or honorarium. Please specify the pharmaceutical company, types of consultancy and dates when fees/honoraria paid: Past Period: Current From Month: From Year: Name of Pharmaceutical Company: Several IQVIA is a contract research organization that performs Type of consultancy: commissioned pharmacoepidemiological studies and thus its employees have been and currently are working in collaboration with several pharmaceutical companies. 2.5 Strategic Advisory Role No (7) Yes (Strategic Advisory role on activities of a pharmaceutical company during the past 3 years of study application? Participation with the right to vote on/influence the output in a (scientific) advisory board/steering committee with the role of providing advice/expressing opinions on the future strategy, direction or development activities of a pharmaceutical company either in terms of general or product-related strategy, regardless of contractual arrangements or any form of remuneration. 2.6 Grant / Funding No (7) Yes (Grant/funding from a pharmaceutical company other than funds contemplated in the concerned study contract?

Refers to a grant or funding from a pharmaceutical company which is currently being received by your research group,

irrespective of whether you are employed or a volunteer, and you receive no personal gain.

SECTION 3: ANY OTHER INTERESTS No 🕢 Yes ()

In this section you should declare any other interests of commercial, financial, institutional or personal nature to be made known to the public.*

Any other relationships/conditions/circumstances that present a potential conflict of interest, including matters relating to members of your family? (*see definition in Annex 1 of ENCePP Code of Conduct)

Further to the interests declared above, I do hereby declare on my honour that I do not have any further interests or facts that should be made public in relation to the conduct of the study.

Should there be any change of the above due to the fact that I acquire additional interests, I shall promptly complete and upload a new Declaration of Interests detailing the changes.

✓ I confirm the information declared on this form is accurate to the best of my knowledge and I consent to my information being stored electronically and published on the <u>EU PAS Register</u>.

Date	14/06/2021
	Date:

Submit Form by Email



INTRODUCTION

This document includes your personal details and your declaration of interests to be made public in line with the provisions of the ENCePP Code of Conduct. All parts must be duly completed. You are responsible for the accuracy and completeness of the submitted information.

The form is designed to be filled in electronically; a copy of the form should be uploaded to the <u>EU PAS</u> <u>Register</u>.

For ENCePP Seal studies only: the completed form is to be transmitted to the ENCePP Secretariat by email.

SECTION 1: PERSONAL DETAILS

First Name:	Majken Borup
Last Name:	Linnemann Jensen
Organisation / Research Centre :	IQVIA
Country:	Denmark
Contact e-mail Address:	majken.linnemann@IQVIA.com
	A non-interventional register-based comparative effectiveness study of rhFSH-alfa reference product vs. highly purified human menopausal gonadotropin or rhFSH-alfa biosimilar products for ovarian stimulation in in vitro fertilization or intracytoplasmic sperm injection treatment in Denmark and Sweden – The Nordic Follitropin Alfa Comparative Effectiveness (NORD-FACE) Study
Study Reference Number: I	EUPAS 4 1 1 7 5
Are you the (Primary) Lead	Investigator of the above study? No ✓ Yes □
Are you an investigator/res	earcher contributing to the above study No 🗌 Yes 🗸

SECTION 2: DECLARATION OF INTERESTS RELATED TO PHARMACEUTICAL INDUSTRY In this section you must declare any interests in the pharmaceutical industry that you currently have or had within the past 3 years. If you have interests to declare please tick 'Yes' to the relevant questions. All questions in this part must be answered. 2.1 Employment Yes () Employment in a pharmaceutical company during past 3 years of study application? Pharmaceutical company includes supply or service companies which contribute to research, development, production and maintenance of a medicinal product. Employment relates to salaries currently being directly paid to you by a pharmaceutical company. 2.2 Financial Interest Yes (Financial interests in the capital of a pharmaceutical company? Financial interests relate to current holding of shares of a pharmaceutical company with the exclusion of independently managed investment funds/pensions schemes that are not exclusively based on the pharmaceutical sector. Please specify type of shares and financial interest (excluding investment funds) of: Share Value (please select) Type of shares or financial interest Less than 10,000 EUR or equivalent Own shares in Novo Nordisk 2.3 Patent No (V) Yes Patent for a medicinal product? Relates to a patent for a medicinal product currently owned by either you as individual or your organisation/ research centre, and you as individual are the beneficiary. 2.4 Consultancy No () Yes (Consultancy for a pharmaceutical company during the past 3 years of study application? Consultancy refers to provision of advice or services to a pharmaceutical company excluding the concerned study and including but not limited to reviewing activities, data monitoring, statistical analysis, end point committees, regardless of contractual arrangements or any form of remuneration such as consulting fees or honoraria. Note that conference/seminar attendance is not considered a consultancy but should be indicated if subject to fee or honorarium. Please specify the pharmaceutical company, types of consultancy and dates when fees/honoraria paid: Period: Past From Year: 2016 From Month: 10 Name of Pharmaceutical Company: Several IQVIA is a contract research organization that performs Type of consultancy: commissioned pharmacoepidemiological studies and thus its employees have been and currently are working in collaboration with several pharmaceutical companies.

2.5 Strategic Advisory Role

Strategic Advisory role on activities of a pharmaceutical company during the past 3 years of study application?

Participation with the right to vote on/influence the output in a (scientific) advisory board/steering committee with the role of providing advice/expressing opinions on the future strategy, direction or development activities of a pharmaceutical company either in terms of general or product-related strategy, regardless of contractual arrangements or any form of remuneration.

Yes (

No 🕢 Yes 🔿

2.6 Grant / Funding

Grant/funding from a pharmaceutical company other than funds contemplated in the concerned study contract?

Refers to a grant or funding from a pharmaceutical company which is currently being received by your research group, irrespective of whether you are employed or a volunteer, and you receive no personal gain.

SECTION 3: ANY OTHER INTERESTS

No 🕢 Yes ()

In this section you should declare any other interests of commercial, financial, institutional or personal nature to be made known to the public.*

Any other relationships/conditions/circumstances that present a potential conflict of interest, including matters relating to members of your family? (*see definition in Annex 1 of ENCePP Code of Conduct)

Further to the interests declared above, I do hereby declare on my honour that I do not have any further interests or facts that should be made public in relation to the conduct of the study.

Should there be any change of the above due to the fact that I acquire additional interests, I shall promptly complete and upload a new Declaration of Interests detailing the changes.

I confirm the information declared on this form is accurate to the best of my knowledge and I consent to my information being stored electronically and published on the EU PAS Register.

FULL NAME:

Majken Borup Linnemann Jensen

Date:

16/06/2021

Submit Form by Email



INTRODUCTION

This document includes your personal details and your declaration of interests to be made public in line with the provisions of the ENCePP Code of Conduct. All parts must be duly completed. You are responsible for the accuracy and completeness of the submitted information.

The form is designed to be filled in electronically; a copy of the form should be uploaded to the $\underline{\text{EU PAS}}$ Register.

For ENCePP Seal studies only: the completed form is to be transmitted to the ENCePP Secretariat by email.

SECTION 1: PERSONAL DETAILS

First Name:	Samron Brhane
Last Name:	Gebregergish
Organisation / Research Centre :	IQVIA
Country:	Sweden
Contact e-mail Address:	samronbrhane.gebregergish@iqvia.com
	A non-interventional register-based comparative effectiveness study of rhFSH-alfa reference product vs. highly purified human menopausal gonadotropin or rhFSH-alfa biosimilar products for ovarian stimulation in in vitro fertilization or intracytoplasmic sperm injection treatment in Denmark and Sweden – The Nordic Follitropin Alfa Comparative Effectiveness (NORD-FACE) Study
Study Reference Number:	EUPAS 4 1 1 7 5
Are you the (Primary) Lead	Investigator of the above study? No \checkmark Yes
Are you an investigator/res	earcher contributing to the above study No Yes

SECTION 2: DECLARATION OF INTERESTS RELATED TO PHARMACEUTICAL INDUSTRY In this section you must declare any interests in the pharmaceutical industry that you currently have or had within the past 3 years. If you have interests to declare please tick 'Yes' to the relevant questions. All questions in this part must be answered. 2.1 Employment No (7) Yes (Employment in a pharmaceutical company during past 3 years of study application? Pharmaceutical company includes supply or service companies which contribute to research, development, production and maintenance of a medicinal product. Employment relates to salaries currently being directly paid to you by a pharmaceutical company. No (Yes (2.2 Financial Interest Financial interests in the capital of a pharmaceutical company? Financial interests relate to current holding of shares of a pharmaceutical company with the exclusion of independently managed investment funds/pensions schemes that are not exclusively based on the pharmaceutical sector. 2.3 Patent No (V) Yes (Patent for a medicinal product? Relates to a patent for a medicinal product currently owned by either you as individual or your organisation/ research centre, and you as individual are the beneficiary. 2.4 Consultancy No () Yes 🕢 Consultancy for a pharmaceutical company during the past 3 years of study application? Consultancy refers to provision of advice or services to a pharmaceutical company excluding the concerned study and including but not limited to reviewing activities, data monitoring, statistical analysis, end point committees, regardless of contractual arrangements or any form of remuneration such as consulting fees or honoraria. Note that conference/seminar attendance is not considered a consultancy but should be indicated if subject to fee or honorarium. Please specify the pharmaceutical company, types of consultancy and dates when fees/honoraria paid: Period: Current Past 12 From Year: 2019 From Month: Name of Pharmaceutical Company: Several Type of consultancy: IQVIA is a contract research organization that performs commissioned pharmacoepidemiological studies and thus its employees have been and currently are working in collaboration with several pharmaceutical companies Please specify the pharmaceutical company, types of consultancy and dates when fees/honoraria paid: Current Period: Past From Month: 106 From Year: 2018 To Month: 11 2019 To Year: Name of Pharmaceutical Company: Several Employment at Ingress-Health, which is a contract research Type of consultancy: organization performing health economics and outcome research studies for pharmaceutical companies. 2.5 Strategic Advisory Role No 🕢 Yes ()

Strategic Advisory role on activities of a pharmaceutical company during the past 3 years of study application?

Participation with the right to vote on/influence the output in a (scientific) advisory board/steering committee with the role of providing advice/expressing opinions on the future strategy, direction or development activities of a pharmaceutical company either in terms of general or product-related strategy, regardless of contractual arrangements or any form of remuneration.

Grant/funding from a pharmaceutical company other than funds contemplated in the concerned study contract?
Refers to a grant or funding from a pharmaceutical company which is currently being received by your research group, irrespective of whether you are employed or a volunteer, and you receive no personal gain.
SECTION 3: ANY OTHER INTERESTS No Yes
In this section you should declare any other interests of commercial, financial, institutional or personal nature to be made known to the public.*
Any other relationships/conditions/circumstances that present a potential conflict of interest, including matters relating to members of your family? (*see definition in Annex 1 of ENCePP Code of Conduct)
Further to the interests declared above, I do hereby declare on my honour that I do not have any further interests or facts that should be made public in relation to the conduct of the study.
Should there be any change of the above due to the fact that I acquire additional interests, I shall promptly complete and upload a new Declaration of Interests detailing the changes.
$\boxed{\prime}$ I confirm the information declared on this form is accurate to the best of my knowledge and I consent to my information being stored electronically and published on the $\underline{\sf EU\ PAS\ Register}$.
FULL NAME: Samron Brhane Gebregergish Date: 15/06/2021

Submit Form by Email

No 🕢 Yes 🔘

2.6 Grant / Funding



INTRODUCTION

This document includes your personal details and your declaration of interests to be made public in line with the provisions of the ENCePP Code of Conduct. All parts must be duly completed. You are responsible for the accuracy and completeness of the submitted information.

The form is designed to be filled in electronically; a copy of the form should be uploaded to the $\underline{\text{EU PAS}}$ Register.

For ENCePP Seal studies only: the completed form is to be transmitted to the ENCePP Secretariat by email.

SECTION 1: PERSONAL DETAILS

First Name:	Katja
Last Name:	Hakkarainen
Organisation / Research Centre :	IQVIA
Country:	Sweden
Contact e-mail Address:	katja.hakkarainen@iqvia.com
	A non-interventional register-based comparative effectiveness study of rhFSH-alfa reference product vs. highly purified human menopausal gonadotropin or rhFSH-alfa biosimilar products for ovarian stimulation in in vitro fertilization or intracytoplasmic sperm injection treatment in Denmark and Sweden – The Nordic Follitropin Alfa Comparative Effectiveness (NORD-FACE) Study
Study Reference Number:	EUPAS 4 1 1 7 5
Are you the (Primary) Lead	d Investigator of the above study? No 🗸 Yes 🗌
Are you an investigator/re	searcher contributing to the above study No Yes

SECTION 2: DECLARATION	OF INTERESTS REI	LATED T	O PH	ARMACEUTICAL	INDUSTRY
In this section you must declare any past 3 years. If you have interests to be answered.					
2.1 Employment		No 🕢	Yes 🔘)	
Employment in a pharmaceutic Pharmaceutical company includes sup and maintenance of a medicinal produpharmaceutical company.	ply or service companies	s which co	ntribute	to research, develop	ment, production
2.2 Financial Interest		No 🕢	Yes 🔾)	
Financial interests in the capit Financial interests relate to current he managed investment funds/pensions	olding of shares of a pha	rmaceutica	al compa		
2.3 Patent		No 🕢	Yes 🔘)	
Patent for a medicinal product Relates to a patent for a medicinal pr centre, and you as individual are the	oduct currently owned by	y either yo	u as ind	lividual or your organ	isation/ research
2.4 Consultancy		No 🔘	Yes 🗸)	
Consultancy for a pharmaceut Consultancy refers to provision of advincluding but not limited to reviewing of contractual arrangements or any for Note that conference/seminar attendation	rice or services to a phar activities, data monitorion from of remuneration sucl	maceutica ng, statisti n as consu	l compa cal anal Iting fee	ny excluding the conc ysis, end point comm es or honoraria.	cerned study and ittees, regardless
Please specify the pharmaceutical compan	y, types of consultancy and	dates wher	n fees/ho	onoraria paid:	
Period:	Past				
From Month: 08 From Year: 20	014				
Name of Pharmaceutical Company:	Several				
Type of consultancy:	IQVIA is a contract rese commissioned pharmacc employees have been a collaboration with sever	pepidemiol nd current	logical s [.] ly are w	tudies and thus its orking in	
2.5 Strategic Advisory Role		No 🕢	Yes ()	
Strategic Advisory role on activities of a pharmaceutical company during the past 3 years of study application? Participation with the right to vote on/influence the output in a (scientific) advisory board/steering committee with the role of providing advice/expressing opinions on the future strategy, direction or development activities of a pharmaceutical company either in terms of general or product-related strategy, regardless of contractual arrangements					

or any form of remuneration.

Grant/funding from a pharmaceutical company other than funds contemplated in the concerned study contract?

Refers to a grant or funding from a pharmaceutical company which is currently being received by your research group, irrespective of whether you are employed or a volunteer, and you receive no personal gain.

SECTION 3: ANY OTHER INTERESTS	No 🕜 Yes 🔾
In this section you should declare any other	interests of commercial financial

institutional or personal nature to be made known to the public.*

Any other relationships/conditions/circumstances that present a potential conflict of interest, including matters relating to members of your family? (*see definition in Annex 1 of ENCePP Code of Conduct)

Further to the interests declared above, I do hereby declare on my honour that I do not have any further interests or facts that should be made public in relation to the conduct of the study.

Should there be any change of the above due to the fact that I acquire additional interests, I shall promptly complete and upload a new Declaration of Interests detailing the changes.

✓ I confirm the information declared on this form is accurate to the best of my knowledge and I consent to my information being stored electronically and published on the <u>EU PAS Register</u>.

FULL NAME:	Katja Hakkarainen	Date:	17/06/2021
------------	-------------------	-------	------------

Submit Form by Email



INTRODUCTION

This document includes your personal details and your declaration of interests to be made public in line with the provisions of the ENCePP Code of Conduct. All parts must be duly completed. You are responsible for the accuracy and completeness of the submitted information.

The form is designed to be filled in electronically; a copy of the form should be uploaded to the $\underline{\text{EU PAS}}$ Register.

For ENCePP Seal studies only: the completed form is to be transmitted to the ENCePP Secretariat by email.

SECTION 1: PERSONAL DETAILS

First Name:	Valerie
Last Name:	Strezsak
Organisation / Research Centre :	EMD Serono, A business of Merck KGaA, Darmstadt, Germany - Global Epidemiology
Country:	United States of America
Contact e-mail Address:	valerie.strezsak@emdserono.com
	A non-interventional register-based comparative effectiveness study of rhFSH-alfa reference product vs. highly purified human menopausal gonadotropin or rhFSH-alfa biosimilar products for ovarian stimulation in in vitro fertilization or intracytoplasmic sperm injection treatment in Denmark and Sweden – The Nordic Follitropin Alfa Comparative Effectiveness (NORD-FACE) Study
Study Reference Number: E	SUPAS 4 1 1 7 5
Are you the (Primary) Lead	Investigator of the above study? No ✓ Yes
Are you an investigator/rese	earcher contributing to the above study No 🗌 Yes 🗸

SECTION 2: DECLARATION OF INTERESTS RELATED TO PHARMACEUTICAL INDUSTRY

In this section you must declare any interests in the pharmaceutical industry that you currently have or had within the past 3 years. If you have interests to declare please tick 'Yes' to the relevant questions. All questions in this part must be answered.

2.1 Employment	No 🔘 Yes 🕜
Pharmaceutical company includes supply or service	y during past 3 years of study application? companies which contribute to research, development, production ent relates to salaries currently being directly paid to you by a
Please specify the pharmaceutical company and dates who	en emp l oyed:
Period:	
From Month: 09 From Year: 2019	
Name of Pharmaceutical Company: EMD Serono,	A business of Merck KGaA, Darmstadt, Germany
Please specify the pharmaceutical company and dates who	en emp l oyed:
Period: Current 🕜 Past	
From Month: 09 From Year: 2017	To Month: 09 To Year: 2019
Name of Pharmaceutical Company: Takeda Pharn	naceutical Company
2.2 Financial Interest	No ○ Yes �
managed investment funds/pensions schemes that	es of a pharmaceutical company with the exclusion of independently are not exclusively based on the pharmaceutical sector.
Please specify type of shares and financial interest (excluded)	
Share Value (please select)	Type of shares or financial interest
More than 10,000 EUR or equivalent	Shares
2.3 Patent	No 🕢 Yes 🔘
Patent for a medicinal product? Relates to a patent for a medicinal product currentle centre, and you as individual are the beneficiary.	y owned by either you as individual or your organisation/ research
2.4 Consultancy	No 🕢 Yes 🔘
Consultancy refers to provision of advice or services including but not limited to reviewing activities, dat of contractual arrangements or any form of remune	by during the past 3 years of study application? Is to a pharmaceutical company excluding the concerned study and a monitoring, statistical analysis, end point committees, regardless eration such as consulting fees or honoraria. Insidered a consultancy but should be indicated if subject to fee or
2.5 Strategic Advisory Pole	No. (A) Yes (

Strategic Advisory role on activities of a pharmaceutical company during the past 3 years of study application?

Participation with the right to vote on/influence the output in a (scientific) advisory board/steering committee with the role of providing advice/expressing opinions on the future strategy, direction or development activities of a pharmaceutical company either in terms of general or product-related strategy, regardless of contractual arrangements or any form of remuneration.

2.6 Grant / Funding	No 🕢 Yes 🔘	

Grant/funding from a pharmaceutical company other than funds contemplated in the concerned study contract?

Refers to a grant or funding from a pharmaceutical company which is currently being received by your research group, irrespective of whether you are employed or a volunteer, and you receive no personal gain.

SECTION 3: A	NY OTHER INTERESTS	No 🕢	Yes 🔘
	n you should declare any other or personal nature to be made		· · · · · · · · · · · · · · · · · · ·
	ships/conditions/circumstances that pre ur family? (*see definition in Annex 1 of		al conflict of interest, including matters relating of Conduct)
	rests declared above, I do hereby decla be made public in relation to the conduc		ur that I do not have any further interests or
	ny change of the above due to the fact t Declaration of Interests detailing the ch		additional interests, I shall promptly complete
	e information declared on this form is ac stored electronically and published on t		est of my knowledge and I consent to my ister.
FULL NAME:	/alerie Strezsak	Date: 16	5/06/2021
	Submit	Form by Email	



INTRODUCTION

This document includes your personal details and your declaration of interests to be made public in line with the provisions of the ENCePP Code of Conduct. All parts must be duly completed. You are responsible for the accuracy and completeness of the submitted information.

The form is designed to be filled in electronically; a copy of the form should be uploaded to the $\underline{\text{EU PAS}}$ Register.

For ENCePP Seal studies only: the completed form is to be transmitted to the ENCePP Secretariat by email.

SECTION 1: PERSONAL DETAILS

First Name:	Patrice			
Last Name:	Verpillat			
Organisation / Research Centre :	Merck Healthcare KGaA - Global Epidemiology			
Country:	Germany			
Contact e-mail Address:	patrice.verpillat@merckgroup.com			
A non-interventional register-based comparative effectiveness study of rhFSH-reference product vs. highly purified human menopausal gonadotropin or rhFSI alfa biosimilar products for ovarian stimulation in in vitro fertilization or intracytoplasmic sperm injection treatment in Denmark and Sweden – The Nor Follitropin Alfa Comparative Effectiveness (NORD-FACE) Study				
Study Reference Number: E	SUPAS 4 1 1 7 5			
Are you the (Primary) Lead	Investigator of the above study? No ✓ Yes			
Are you an investigator/rese	earcher contributing to the above study No 🗌 Yes 🗸			

SECTION 2: DECLARATION OF INTERESTS RELATED TO PHARMACEUTICAL INDUSTRY In this section you must declare any interests in the pharmaceutical industry that you currently have or had within the past 3 years. If you have interests to declare please tick 'Yes' to the relevant questions. All questions in this part must be answered. 2.1 Employment No Yes Employment in a pharmaceutical company during past 3 years of study application?

2.1 Employment	No O Yes 🗸
	during past 3 years of study application? companies which contribute to research, development, production nt relates to salaries currently being directly paid to you by a
Please specify the pharmaceutical company and dates whe	n employed:
Period:	
From Month: 01 From Year: 2017	
Name of Pharmaceutical Company: Merck Healtho	are KGaA
2.2 Financial Interest	No ○ Yes ②
	s of a pharmaceutical company with the exclusion of independently are not exclusively based on the pharmaceutical sector.
Share Value (please select)	Type of shares or financial interest
More than 10,000 EUR or equivalent	Shares
2.3 Patent	No 🕢 Yes 🔾
Patent for a medicinal product? Relates to a patent for a medicinal product currently centre, and you as individual are the beneficiary.	owned by either you as individual or your organisation/ research
2.4 Consultancy	No 🕢 Yes 🔾
Consultancy refers to provision of advice or services including but not limited to reviewing activities, data of contractual arrangements or any form of remune	y during the past 3 years of study application? to a pharmaceutical company excluding the concerned study and a monitoring, statistical analysis, end point committees, regardless ration such as consulting fees or honoraria. sidered a consultancy but should be indicated if subject to fee or
2 E Stratogic Advisory Polo	No. (Voc. (

2.5 Strategic Advisory Role

Strategic Advisory role on activities of a pharmaceutical company during the past 3 years of study application?

Participation with the right to vote on/influence the output in a (scientific) advisory board/steering committee with the role of providing advice/expressing opinions on the future strategy, direction or development activities of a pharmaceutical company either in terms of general or product-related strategy, regardless of contractual arrangements or any form of remuneration.

2.6 Grant / Funding

No ⊘ Yes ⊖

Grant/funding from a pharmaceutical company other than funds contemplated in the concerned study contract?

Refers to a grant or funding from a pharmaceutical company which is currently being received by your research group, irrespective of whether you are employed or a volunteer, and you receive no personal gain.

SECTION 3: ANY OTHER INTERESTS	No	\bigcirc	Yes 🔘		
In this section you should declare any oth institutional or personal nature to be made				•	
Any other relationships/conditions/circumstances that pr to members of your family? (*see definition in Annex 1 α				interest, including matters re	elatin
Further to the interests declared above, I do hereby dec facts that should be made public in relation to the condu			our that I do	not have any further interes	ts or
Should there be any change of the above due to the fact and upload a new Declaration of Interests detailing the c		quire a	additional into	erests, I shall promptly com	plete
\checkmark I confirm the information declared on this form is accurate to the best of my knowledge and I consent to my information being stored electronically and published on the <u>EU PAS Register</u> .					
FULL NAME: Patrice Verpillat	Date:	16	5/06/2021		

Submit Form by Email